<- Go Home
IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Market Cap
$76.6M
Volume
310.1K
Cash and Equivalents
$30.6M
EBITDA
$17.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$5.5M
Profit Margin
3.79%
52 Week High
$22.50
52 Week Low
$0.92
Dividend
N/A
Price / Book Value
0.76
Price / Earnings
-1.44
Price / Tangible Book Value
0.76
Enterprise Value
-$27.7M
Enterprise Value / EBITDA
-1.57
Operating Income
$10.3M
Return on Equity
47.82%
Return on Assets
2.89
Cash and Short Term Investments
$104.3M
Debt
N/A
Equity
$100.9M
Revenue
$145.1M
Unlevered FCF
$23.0M
Sector
Biotechnology
Category
N/A